A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Cancer Immunology, Immunotherapy, 06/13/2012
de Vos van Steenwijk PJ et al. – The cytokine profile associated with HPV16–specific proliferation varied from robust type 1 to dominant type 2 responses. No conclusions could be drawn on vaccine–enhanced T–cell infiltration of the lesion, and there was no HPV clearance at the time of LEEP excision. Thus, vaccination of HSIL patients results in increased HPV16–specific T–cell immunity. Further development of this type of treatment relies on the ability to motivate patients and in the reduction in the side effects.
